Aditxt, Inc. received notice from the Nasdaq Hearings Panel denying its request to maintain its listing on the exchange. Trading of the company's common stock (ADTX) will be suspended at the market open on June 25, 2026. The delisting follows failures to meet Nasdaq's minimum bid price of $1.00 and the minimum stockholders' equity requirement of $2.5 million. The company reported a stockholders' equity deficit of $(35,174,386) as of March 31, 2026. The company attempted to present a compliance plan involving a $150 million business combination of its subsidiary, Ignite Proteomics, with a SPAC, but the Panel found the plan unconvincing.